Exelixis Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for EXEL, updated each market day.
EXEL AI Sentiment
AI sees no strong directional signal for Exelixis Inc stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Sector
Exchange
Market Cap
$14,492,751,165
Cap Tier
Employees
1,077
Headquarters
ALAMEDA, CA
Listed Since
April 11, 2000
Website
EXEL Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
EXEL Volatility
Exelixis Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
